SEC-sourced researchBeta

XERS

Xeris Biopharma Holdings, Inc.

US markets

Data passport

CIK: 0001867096
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Oct 2, 2026
SEC registry record: Operating company

Last updated: Oct 5, 2026, 9:04 PM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

XERS · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	163,914,000.0000	Mar 2, 2026
December 2024	203,070,000.0000	Mar 2, 2026
December 2025	291,845,000.0000	Mar 2, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	291,845,000.0000	554,000.0000	28,626,000.0000	383,527,000.0000	369,838,000.0000	Mar 2, 2026
December 2024	203,070,000.0000	-54,836,000.0000	-36,981,000.0000	323,060,000.0000	352,675,000.0000	Mar 2, 2026
December 2023	163,914,000.0000	-62,255,000.0000	-47,023,000.0000	—	—	Mar 2, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$291.85M	December 2025	Mar 2, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$203.07M	December 2024	Mar 2, 2026	10-K
Net incomeNetIncomeLoss	$554K	December 2025	Mar 2, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	$28.63M	December 2025	Mar 2, 2026	10-K
Total assetsAssets	$383.53M	December 2025	Mar 2, 2026	10-K
Total liabilitiesLiabilities	$369.84M	December 2025	Mar 2, 2026	10-K

New filings

Explore methodology ↗